139 related articles for article (PubMed ID: 21642860)
1. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
Gottlin EB; Bentley RC; Campa MJ; Pisetsky DS; Herndon JE; Patz EF
J Thorac Oncol; 2011 Oct; 6(10):1687-90. PubMed ID: 21642860
[TBL] [Abstract][Full Text] [Related]
2. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Gomez-Roca C; Raynaud CM; Penault-Llorca F; Mercier O; Commo F; Morat L; Sabatier L; Dartevelle P; Taranchon E; Besse B; Validire P; Italiano A; Soria JC
J Thorac Oncol; 2009 Oct; 4(10):1212-20. PubMed ID: 19687761
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
7. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
10. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
12. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up.
Toomey D; Smyth G; Condron C; Kelly J; Byrne AM; Kay E; Conroy RM; Broe P; Bouchier-Hayes D
Int J Cancer; 2003 Jan; 103(3):408-12. PubMed ID: 12471625
[TBL] [Abstract][Full Text] [Related]
14. Association of FOXP3 expression with non-small cell lung cancer.
Dimitrakopoulos FI; Papadaki H; Antonacopoulou AG; Kottorou A; Gotsis AD; Scopa C; Kalofonos HP; Mouzaki A
Anticancer Res; 2011 May; 31(5):1677-83. PubMed ID: 21617226
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer].
Wang DF; Zeng CG; Lin YB; Hou JH; Zhu ZH
Ai Zheng; 2006 Mar; 25(3):359-62. PubMed ID: 16536995
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of IGF1R expression in non-small-cell lung cancer.
Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
Le QT; Chen E; Salim A; Cao H; Kong CS; Whyte R; Donington J; Cannon W; Wakelee H; Tibshirani R; Mitchell JD; Richardson D; O'Byrne KJ; Koong AC; Giaccia AJ
Clin Cancer Res; 2006 Mar; 12(5):1507-14. PubMed ID: 16533775
[TBL] [Abstract][Full Text] [Related]
18. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
19. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
20. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]